EQ
Equillium, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- S Feb 19 1 insider sell $328.1K at $1.76
- S Mar 9 to Mar 13 2 days of insider sells: $663.3K by 1 insider, avg $2.20
- R Mar 25 Equillium reported $0 revenue for Q4 and full-year 2025, a sharp dec…
- E May 20 FDA: Equillium to Host Virtual Investor Event to Share New Insi…
- S May 27 to Jun 5 4 days of insider sells: $1.2M by 3 insiders, avg $3.02
- A Jul 13 Piper Sandler initiates
- E Sep 29 FDA: Equillium Announces Poster Presentations at the 7th Intern…
- E Oct 5 FDA: Equillium Receives Australian Regulatory Clearance to Init…
Signal stack
Where each data set points today.
- InsidersBEARISH
3 insiders sold $2.2M.
- InstitutionsMIXED
Q2 2026: 6 added (0 new), 6 trimmed or exited.
- AnalystsBULLISH
17 of 18 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.051 → −$0.050 over 90 days. 2 up, 3 down in 30 days.
- Short sellersSTEADY
Short interest +0.7% to 5.54M shares. 6.0 days to cover, ≈8.7% of shares.
- TrendDOWNTREND
33% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | $4.4M |
| BALYASNY ASSET MANAGEMENT L.P. | NEAR_EXIT | $1.1M |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | $1.0M |
| BlackRock, Inc. | DOUBLED | $913.3K |
| CITADEL ADVISORS LLC | TRIM | $318.9K |
| JANE STREET GROUP, LLC | TRIM | $304.7K |
| CITIGROUP INC | DOUBLED | $104.6K |
| MORGAN STANLEY | ADD | $95.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is below the lowest target. Median implies +469%.Targets as of Oct 26, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 4, 2026 | Roth Capital REITERATE | Buy |
| Jul 13, 2026 | Piper Sandler INITIATE | Overweight |
| Jun 2, 2026 | Roth Capital REITERATE | Buy |
| May 28, 2026 | Leerink Partners UPGRADE | Outperform |
| May 28, 2026 | Roth Capital REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Zedelmayer Christine Sr. Vice President and COO | SELL | $42.7K |
| Jun 5, 2026 | Zedelmayer Christine Sr. Vice President and COO | EXERCISE | $11.4K |
| Jun 5, 2026 | Connelly Stephen President and CSO | SELL | $91.1K |
| Jun 4, 2026 | Connelly Stephen President and CSO | SELL | $632.8K |
| May 28, 2026 | Zedelmayer Christine Sr. Vice President and COO | SELL | $90.0K |
| May 28, 2026 | Zedelmayer Christine Sr. Vice President and COO | EXERCISE | $12.3K |
| May 28, 2026 | Zedelmayer Christine Sr. Vice President and COO | EXERCISE | $11.4K |
| May 28, 2026 | Zedelmayer Christine Sr. Vice President and COO | SELL | $542.00 |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.05 | -$0.06–-$0.04 | +2.8% | $0.00 |
| Next Q | -$0.06 | -$0.07–-$0.03 | +2.4% | $0.00 |
| Current FY | -$0.21 | -$0.22–-$0.17 | +0.0% | $0.00 |
| Next FY | -$0.24 | -$0.36–-$0.15 | -1.2% | $0.00 |
Short side
FINRA· Sep 30, 2026SecBot reports
7 filings · 5 press releases · 0 bullish · 1 bearish · 6 neutral- NEUTRAL PRESS RELEASEOct 26, 2026
Equillium dosed the first subject in a Phase 1 trial of EQ504, an oral AhR modulator for inflammatory diseases, triggering a $20M milestone closing under its August 2025 equity private placement. The company expects to report topline Phase 1 data in Q2 2027 and has cash runway into 2029.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KOct 5, 2026
Equillium received regulatory clearance from Australian authorities (HREC and TGA) to begin a…
Monitor for initial safety and PK readouts from the Phase 1 trial, which are likely 6-12 months away. The key value inflection for EQ504 will be Phase 2 proof-of-concept data, not this Phase 1 start.
- NEUTRAL PRESS RELEASEOct 5, 2026
Equillium received Australian regulatory clearance (HREC approval and TGA clearance) to begin a…
Monitor for first-patient-dosed announcement (expected early November 2026) and subsequent Phase 1 topline data (~mid-2027). No near-term binary catalyst; stock movement likely limited until…
- NEUTRAL PRESS RELEASESep 29, 2026
Equillium announced new preclinical data for its EQ504 program, a selective AhR modulator for…
Monitor for initiation of a Phase 1 study of EQ504, which the forward-looking statements reference as an expected milestone. No near-term catalyst from this preclinical data alone.
All EQ filing & press-release reports (12)
- PRESS-RELEASE reportOct 26, 2026
- 8-K reportOct 5, 2026
- PRESS-RELEASE reportOct 5, 2026
- PRESS-RELEASE reportSep 29, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportMay 29, 2026
- PRESS-RELEASE reportMay 20, 2026
- EFFECT reportApr 17, 2026
- DEFA14A reportApr 15, 2026
- S-3 reportApr 7, 2026
- PRESS-RELEASE reportMar 25, 2026